Featured

Status

All Statuses
  • Completed64

Health Topics

Any Category
Psychiatry and Psychology
Clear Filters

Search Clinical Trials

64 Results
Completed
NAC as a Potential Treatment for Methamphetamine Dependence
N-acetyl-l-cysteine (NAC) treatment is associated with reduced susceptibility to reinstatement of cocaine seeking behavior in rats (Baker et al 2002) and with reduced cue-induced craving in cocaine-dependent human volunteers (LaRowe …
Baylor Role: Lead Sponsor
Completed
Pharmacogenetics of Doxazosin for Cocaine Dependence
The NE system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. The results of this study will provide medical safety data on the …
Baylor Role: Lead Sponsor
Completed
The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine
Primary Objective: The primary objective is to determine the safety of treatment with doxazosin in cocaine-dependent volunteers by examining hemodynamic and subjective effects of administration of ascending doses of cocaine …
Baylor Role: Lead Sponsor
Completed
The Efficacy of Doxazosin for Cocaine Users
The NE system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. The results of this study will provide medical safety data on the …
Baylor Role: Lead Sponsor
Completed
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
HYPOTHESES Primary Hypothesis: Compared to placebo treatment, nepicastat-treated OIF/OEF veterans with PTSD will have significantly reduced PTSD hyperarousal symptoms as defined by the Clinician Administered PTSD Scale [CAPS], subscale D …
Baylor Role: Collaborator
Completed
Rivastigmine as a Treatment for Methamphetamine Dependence
We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. …
Baylor Role: Lead Sponsor
Completed
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to …
Baylor Role: Lead Sponsor
Completed
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
The purpose of this study is to evaluate the interactions between cocaine and oral rivastigmine and between cocaine and oral huperzine A (HupA). The following Specific Aims are proposed: 1. …
Baylor Role: Lead Sponsor
Completed
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a …
Baylor Role: Lead Sponsor
Completed
Expressive Writing for Co-Occurring Depression and Alcohol Misuse
Expressive writing applied to a variety of populations (e.g., HIV, cancer, PTSD, depression) has been associated with health improvements, reductions in symptoms of emotional distress, and one preliminary study found …
Baylor Role: Lead Sponsor